{
    "clinical_study": {
        "@rank": "72237", 
        "acronym": "ASCT", 
        "arm_group": {
            "arm_group_label": "allogeneic stem cell transplantation", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to examine the toxicity of using allogeneic stem cell\n      transplantation for treatment of subjects with relapsed or refractory Ewing Sarcoma (ES) and\n      rhabdomyosarcoma.  Donors will consist of either Human Leukocyte Antigen identical (HLA)or\n      9/10 (A, B, C, DR, DQ [A, B, C, are Class I markers for HLA and DR and DQ are Class II\n      markers for Matching for Transplant for Donors to match with recipient]) matched related or\n      unrelated donors.  Specifically, we will examine:\n\n        -  The toxicity of allogeneic stem cell transplant (SCT) in this patient population, as\n           related to incidence of grade 3-4 acute Graft Verse Host Disease (GVHD).\n\n        -  The incidence of transplant related mortality at 100 days."
        }, 
        "brief_title": "A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory EWING SARCOMA and RHABDOMYOSARCOMA", 
        "condition": [
            "Ewing Sarcoma", 
            "Rhabdomyosarcoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Rhabdomyosarcoma", 
                "Sarcoma, Ewing's", 
                "Sarcoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients aged 0-30 years with relapsed or therapy refractory Ewings sarcoma or\n             rhabdomyosarcoma, excluding patients with brain metastases.\n\n          -  Patients who have received a prior autologous stem cell transplant are eligible.\n\n          -  Related and unrelated marrow and peripheral blood stem donors must be 9/10 or 10/10\n             (HLA A, B, C, DR, DQ) matched with the recipient.\n\n          -  Patients with an isolated local recurrence of their tumor (in the site of the primary\n             tumor) greater than 1 year after completing therapy are excluded, as these patients\n             could be cured with local therapy alone.\n\n          -  As a part of the standard of care for pre-transplant evaluation, subjects will be\n             tested for exposure to viral agents such as hepatitis B, C, Human T-Lymphotropic\n             Verse (HTLV)-1/2, and HIV.\n\n          -  Subjects testing positive for HIV may be rejected as candidates for transplantation,\n             based on the clinical judgment of the stem cell transplant physician.\n\n        Exclusion Criteria:\n\n          -  Organ dysfunction: Patients who have the following levels of organ system dysfunction\n             are not eligible:\n\n               -  Cardiac: Ejection Fraction less than 50 precent\n\n               -  Renal: Est. Creatinine Clearance less than 50 Hepatic: Bilirubin greater than\n                  3.0\n\n               -  Pulmonary: Diffusing Capacity for Carbon Monoxide (DLCO) less than 70 precent,\n                  or for patient who cannot cooperate with pulmonary function testing, O2\n                  saturation less than 95 precent on room air.\n\n          -  Performance status:\n\n               -  Lansky performance less than 70;\n\n               -  Eastern Cooperative Oncology Group (ECOG) status greater than 2\n\n          -  Pregnant females will not be allowed to participate in this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "30 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01969942", 
            "org_study_id": "13.0176"
        }, 
        "intervention": {
            "arm_group_label": "allogeneic stem cell transplantation", 
            "intervention_name": "allogeneic stem cell transplantation", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Ewings sarcoma", 
            "rhabdomyosarcoma"
        ], 
        "lastchanged_date": "October 28, 2013", 
        "link": {
            "description": "University of Louisville Peds--Heme/Onc", 
            "url": "https://louisville.edu/medschool/pediatrics/clinical/sections-divisions/hem-onc"
        }, 
        "location": {
            "contact": {
                "email": "k0luca01@louisville.edu", 
                "last_name": "Kenneth Lucas, M.D.", 
                "phone": "502-852-8450"
            }, 
            "facility": {
                "address": {
                    "city": "Louisville", 
                    "country": "United States", 
                    "state": "Kentucky", 
                    "zip": "40202"
                }, 
                "name": "Pediatric Hematology/Oncology University of Louisville"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory EWING SARCOMA and RHABDOMYOSARCOMA", 
        "overall_contact": {
            "email": "k0luca01@louisville.edu", 
            "last_name": "Kenneth Lucas, M.D.", 
            "phone": "502-852-8450"
        }, 
        "overall_contact_backup": {
            "email": "bgcoy001@louisville.edu", 
            "last_name": "Belinda Coy", 
            "phone": "502-852-8450"
        }, 
        "overall_official": {
            "affiliation": "University of Louisville", 
            "last_name": "Kenneth Lucas, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Development of Grade 3-4 GVHD", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01969942"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Louisville", 
            "investigator_full_name": "Kenneth Lucas", 
            "investigator_title": "Division Cheif", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of Louisville", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Louisville", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}